Currently Viewing:
The Academy of Managed Care Pharmacy (AMCP) 2018
Specialty Drug Pipeline Review Focuses on Competition, Cancer Drugs
April 24, 2018
Dr Robert Navarro Discusses Progress in Shift to Value-Based Care
April 24, 2018
Brian Litten Outlines How Medication Therapy Management Can Address Opioid Misuse
April 24, 2018
Who Decides What Value Looks Like in US Healthcare?
April 24, 2018
Dr Brandon Newman Discusses Payer, Academic Medical Center Collaboration
April 25, 2018
Dr Aimee Tharaldson Discusses Key Market Trends in Specialty Pharmacy
April 25, 2018
Migraines in the US Are More Than Just a Pain Problem
April 25, 2018
Market Access Teams Face New Challenges in Pharma
April 25, 2018
Cardiologist Talks About Value of Monoclonal Antibody Evolocumab
April 26, 2018
Currently Reading
Dr Somali Burgess on the Role of Patient-Reported Outcomes in Managed Care Pharmacy
April 26, 2018
Navigating the Rocky Waters to Value-Based Healthcare
April 26, 2018
Hemophilia: Treatment Landscape, Costs, and Disease Management
April 26, 2018
Dr Aimee Tharaldson on Recently Approved Specialty Drugs, Upcoming Approvals to Watch
May 05, 2018
Dr Calvin Knowlton Outlines Benefits Seen From Enhanced Medication Therapy Management
May 06, 2018
The Rise of Orphan Drugs for Rare Diseases
May 07, 2018
Dr Robert Navarro Foresees Unintended Consequences From Shift to Value-Based Care
May 12, 2018
Dr Kimberly Lenz: Identifying Patients Most at Risk For Substance Abuse
May 13, 2018
Brian Litten Outlines Challenges With Adopting Medication Therapy Management Services
May 17, 2018
Dr Tina Joseph Outlines Pharmacists' Role in Managing Chronic Diseases, Value-Based Care Models
May 19, 2018
Dr Calvin Knowlton on Innovative Practices in Enhanced Medication Therapy Management
May 20, 2018
Dr Ashley Pappas Discusses Collaboration Between Academic Centers and Payers
May 24, 2018
Dr Robert Navarro on Pharma Implementing Value, Best Practices for Value-Based Contracts
May 25, 2018
Drug Approvals That Dr Aimee Tharaldson Is Keeping an Eye on for 2019
May 27, 2018
Dr Kimberly Lenz on Implementing, Enforcing Appropriate Opioid Prescribing
June 04, 2018

Dr Somali Burgess on the Role of Patient-Reported Outcomes in Managed Care Pharmacy

We may not be ready for patient-reported outcomes (PROs) to be the sole decision-maker yet, but the trend is toward PROs being included more and more in value-based processes, explained Somali Burgess, PhD, senior director, Xcenda.


The United States may not be ready for patient-reported outcomes (PROs) to be the sole decision maker in the contracting process yet, but the trend is toward PROs being included more and more in value-based processes, explained Somali Burgess, PhD, senior director, Xcenda.

Transcript

How has the role of patient-reported outcomes in managed care pharmacy changed over recent years?

I am aware that there’s ongoing discussion around the importance of using patient-reported outcomes, or PROs, or PRO measures, and you’ll see it sometimes referred to as PROMs in value-based payment models as they relate to healthcare delivery, healthcare models, treatment patterns, treatment guidelines. But, I have to say that I haven’t seen as much discussion as it relates to drug pricing and contracting yet. And I think that there are still challenges that payers are facing to get us to that point of recognizing the importance of patient-reported outcomes measures, how they fit into the model, how they fit into the contracting process.

Overall, there’s also a lack, I feel, of consensus among drug manufacturers to realize how to use them but also to determine which validated measures should be used. So, as long as there’s a lack of consensus, it’s difficult to come to that standardized or that decision on which to use and how to use. While you can definitely use PRO measures to demonstrate efficacy, as part of a value-based model or the contracting process, there are challenges around collecting that data because there isn’t agreement on which ones to use. The perspective of the patient and the clinician has to be taken into consideration, and then to have a standardized method of data collection.

So, we may not be ready for patient-reported outcome measures to be sole decision-making points yet, but they are definitely being included, and I feel the trend is towards including PRO measures more and more in that value-based process.

 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up